Trial Profile
A single arm, multicentric, open label, efficacy and safety study of Docetaxel Lipid Suspension for Injection of Intas Pharmaceuticals Limited, India in patients with inoperable locally advanced squamous cell carcinoma of the head and neck (SCCHN)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2018
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Intas Pharmaceuticals
- 25 Jun 2018 New trial record